Fintech PR
JFF’s Corporate Action Platform Provides Fortune 500 Companies with a Road Map for the Future of Work
![](https://thefintechbuzz.com/wp-content/uploads/2019/06/13-12.jpg?fit=1200%2C800&ssl=1)
JFF, a national nonprofit that drives transformation in the American workforce and education systems, today announced the launch of an ambitious framework to define a new category of employers adopting talent strategies that make a positive impact on workers, communities, and the bottom line. Developed with support from JPMorgan Chase, JFF’s Corporate Action Platform is designed to equip companies with evidence-based strategies they can use to boost economic mobility among frontline, entry-level, and low- and middle-skilled workers who are at risk of being displaced by artificial intelligence and automation.
“Businesses can do more than simply react to—or navigate around—skill and equity gaps. They can take action by embracing strategies that affect both individual and collective outcomes,” said Maria Flynn, president and CEO of JFF. “This work reflects an awakening among companies that recognize that building tomorrow’s talent pipeline not only enables sustained economic growth, but also provides a powerful competitive advantage.”
A primary component of the Corporate Action Platform is the Talent Framework. Rooted in the experience of companies like Patagonia, Unilever, IBM, and Disney, the Talent Framework was designed to mobilize and support companies as they move along the path to becoming Impact Employers.
The Framework includes both traditional components of corporate talent strategy—like recruiting and retaining employees—and emerging practices for reskilling and offboarding workers displaced by globalization or new technologies. Each of the six components, or levers, of the Framework represents a business area in which companies can modify existing practices to achieve significant returns. JFF will provide strategic assistance to companies to support implementation of high-impact solutions, including the design and execution of effective worker transition programs and benefits packages that include education and tuition support.
“As technology transforms the workplace, we have to get serious about new-skilling our talent,” said Jennie Sparandara, head of workforce initiatives, global philanthropy, at JPMorgan Chase. “Addressing this challenge requires deliberate action to ensure we’re doing everything we can to spread prosperity more widely and giving those left behind a chance to learn the skills they need to get in-demand jobs.”
JFF’s introduction of its Corporate Action Platform comes as the nation’s largest companies struggle to fill open positions and turnover rates continue to soar. Recent research suggests that more than two-thirds of employers report talent shortages and nearly a quarter say they’re having more difficulty finding qualified candidates now than they were last year. These skill and talent gaps stem, in part, from the impact of technological change on the global labor market. According to the World Economic Forum’s The Future of Jobs 2018 report, 50 percent of employers expect that automation will lead to a reduction in their full-time workforces by 2022—and more than half of the world’s workers will require significant reskilling.
“The Corporate Action Platform defines a body of work that moves talent practices beyond the pragmatic needs of individual companies,” said Josh Bersin, a talent development expert and global industry analyst. “This framework goes beyond good corporate citizenship to help redefine talent practices in a way that reflects the new relationship between workers and employers as the labor market evolves.”
In the fall, JFF and JPMorgan Chase will host a series of events for corporate leaders to discuss talent strategies that provide economic value for businesses while spurring economic mobility for workers. For more information about the initiative, visit JFF’s Corporate Action Platform webpage.
SOURCE JFF
Fintech PR
Invitation to presentation of EQT AB’s Q1 Announcement 2024
![invitation-to-presentation-of-eqt-ab’s-q1-announcement-2024](https://thefintechbuzz.com/wp-content/uploads/2024/04/51875-invitation-to-presentation-of-eqt-abs-q1-announcement-2024.png)
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
Fintech PR
Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs
![kia-presents-roadmap-to-lead-global-electrification-era-through-evs,-hevs-and-pbvs](https://thefintechbuzz.com/wp-content/uploads/2024/04/51877-kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs.jpg)
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
Fintech PR
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
![biovaxys-technology-corp.-provides-bi-weekly-mcto-status-update](https://thefintechbuzz.com/wp-content/uploads/2024/04/51873-biovaxys-technology-corp-provides-bi-weekly-mcto-status-update.jpg)
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
“Grand Huangshan” Debuts at the 2024 World Brand Moganshan Conference
-
Latest News6 days ago
AI-powered Panax raises $15m to reshape cash flow management
-
Latest News7 days ago
Yili’s 2023 Revenue Reaches 126.2 Billion Yuan, Leading Global Dairy Industry towards Healthy and Sustainable Development
-
Latest News6 days ago
Egypt’s Swypex launches an all-in-one fintech platform after $4m seed round
-
Latest News6 days ago
Sweden’s Mitigram names Pedram Tadayon as new CEO
-
Latest News6 days ago
Sobha Developers bring to Singapore an Exclusive Dubai Property Showcase
-
Latest News6 days ago
South African fintech Lesaka snaps up Adumo in $86m deal
-
Latest News5 days ago
Al Hassan Ghazi Ibrahim Shaker Co. announces a strong start to FY24, reporting a 12.09% YoY increase in net profit to reach SAR 32.25 million in Q1-FY24